According to the above findings, in clinical work, for patients with preoperative LMR ≤3.4, cirrhosis, positive AFP, or preoperative imaging suggesting that the tumor diameter is greater than 50 mm, postoperative combination of further adjuvant therapeutic measures can be recommended to prevent the occurrence of MVI, and the frequency of follow‐up within 3 years after surgery should also be increased to detect early recurrence and give timely interventions to improve the prognosis of HCC patients. The gene discussed is AFP; the disease is hepatocellular carcinoma.